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The influenza A virus M2 ion channel protein has the longest cytoplasmic tail (CT) among the three viral envelope proteins and
is well conserved between different viral strains. It is accessible to the host cellular machinery after fusion with the endosomal
membrane and during the trafficking, assembly, and budding processes. We hypothesized that identification of host cellular in-
teractants of M2 CT could help us to better understand the molecular mechanisms regulating theM2-dependent stages of the
virus life cycle. Using yeast two-hybrid screening withM2 CT as bait, a novel interaction with the human annexin A6 (AnxA6)
protein was identified, and their physical interaction was confirmed by coimmunoprecipitation assay and a colocalization study
of virus-infected human cells. We found that small interfering RNA (siRNA)-mediated knockdown of AnxA6 expression signifi-
cantly increased virus production, while its overexpression could reduce the titer of virus progeny, suggesting a negative regula-
tory role for AnxA6 during influenza A virus infection. Further characterization revealed that AnxA6 depletion or overexpres-
sion had no effect on the early stages of the virus life cycle or on viral RNA replication but impaired the release of progeny virus,
as suggested by delayed or defective budding events observed at the plasmamembrane of virus-infected cells by transmission
electronmicroscopy. Collectively, this work identifies AnxA6 as a novel cellular regulator that targets and impairs the virus bud-
ding and release stages of the influenza A virus life cycle.
Influenza A virus (IAV) is an enveloped virus with a segmentednegative-sense RNA genome. The eight RNA segments encode
11 proteins (44). Influenza virus is pleomorphic (23), forming
spherical virions that are100 nm in diameter as well as filamen-
tous virions that are 100 nm in diameter and over 20 m in
length. The viral lipid envelope, derived by budding from the api-
cal plasma membrane of the host cell, contains two major enve-
lope glycoproteins, the receptor-binding/membrane fusion pro-
tein hemagglutinin (HA) and the enzyme neuraminidase (NA). A
third minor (16 to 20 molecules/virion) integral membrane
protein, M2, is a proton-selective ion channel that allows virion
interior acidification for efficient uncoating after fusion in endo-
somes. M2 contains 97 amino acid residues and assembles into a
homotetramer. This small type III integral membrane protein
contains a single 19-residue transmembrane domain that forms
the pore of the ion channel, a short (24-residue) amino-terminal
ectodomain, and a long (54-residue) carboxy-terminal cytoplas-
mic domain (27, 34, 45). This cytoplasmic tail (CT) is highly con-
served among viral strains (57).
In the early stages of the replication cycle, after virus internal-
ization by endocytosis, endosomal acidification activates M2 ion
channel activity, causing acidification of the virus interior and
leading to dissociation of the matrix protein M1 from the viral
ribonucleoprotein (vRNP) complex (reviewed in reference 47).
M2 is the target of the antiviral drug amantadine, which inhibits
M2 ion channel activity, thus preventing M1-vRNP dissociation
and virus uncoating (reviewed in reference 46). M2 also functions
to equilibrate the pH gradient between the lumen of the trans-
Golgi network (TGN) and the cytoplasm to prevent premature
low-pH-dependent conformational changes of HA for some viral
strains (9). M2 ion channel activity is also required for activation
of inflammasomes by perturbing the ion concentration in the
Golgi compartment (30).
In addition to ion channel activity, Gannagé et al. reported a
role of M2 in autophagy (17). M2 blocks autophagosome matu-
ration, preventing fusion with the lysosome and significantly af-
fecting host cell apoptosis. Recent work has also suggested thatM2
CT, in particular the amphipathic helix residues 44 to 62,may play
a crucial role in virus assembly and budding (reviewed in refer-
ences 41 and 51). Indeed, M2 CT interacts with M1 and mediates
budding of filamentous virions by stabilizing the virus budding
site (6, 31, 38, 39, 49, 50). It is also important for vRNP incorpo-
ration and the production of infectious virions (20, 38, 39). Re-
cently, Rossman et al. indicated that theM2CT amphipathic helix
modifies membrane curvature at the neck of the budding virus in
a cholesterol-dependent manner, causing membrane scission and
completion of the budding process with the release of the progeny
virion (50).
Altogether, these studies support the notion that M2 is an es-
sential multifunctional viral protein that plays important roles at
many steps of the virus life cycle. However, little is known about
host factors that interact with M2. Few host cell interactants have
been identified, and the functional relevance of these interactions
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is not fully determined (21, 55). In this study, we used a yeast
two-hybrid (Y2H) system to screen a human placenta cDNA
library to identify host proteins that interact with M2 CT. We
hypothesized that cellular factors interacting with M2 CT could
either help or restrict processes involvingM2. The human protein
annexin A6 (AnxA6), a Ca2- and phospholipid-binding protein,
was identified as a novel cellular interactant ofM2, and their phys-
ical interaction was confirmed in virus-infected human cells. By
modulating the expression of AnxA6, we found that AnxA6 neg-
atively regulates IAV infection by impairing virus budding with-
out affecting the early steps of the virus life cycle and virus repli-
cation.
MATERIALS AND METHODS
Yeast two-hybrid screening. Bait cloning and Y2H screening with influ-
enza A virus M2 CT (from strain A/Goose/Guangdong/1/96; GenBank
accession no. 81975894) as bait were performed by Hybrigenics, S.A.,
Paris, France. Briefly, M2 CT was subcloned into the pB27 vector, en-
abling its fusion with the LexA binding domain. The bait construct
pM2/CT was transformed into the L40GAL4 yeast strain (16) and then
mated with the Y187 yeast strain transformed by a random-primed hu-
man placenta cDNA library containing 10 million independent frag-
ments. After selection on medium lacking leucine, tryptophan, and histi-
dine, the 273 positive clones were picked. The corresponding prey
fragments were subjected to PCR and sequencing. Sequences were then
filtered, divided into contigs, and compared to the latest release of the
GenBank database by using BLASTN. A predicted biological score was
attributed to assess the reliability of the interaction, as described earlier
(15).
Cells and viruses.Human embryonic kidney (293T), human alveolar
basal epithelial (A549), human vulval squamous epithelial (A431), and
Madin-Darby canine kidney (MDCK) cells were all purchased from
ATCC and grown in Dulbecco’s modified Eagle’s medium (DMEM) (In-
vitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum
(FBS), 100 U/ml penicillin, and 100 g/ml streptomycin (Invitrogen,
Carlsbad, CA).
Influenza A virus strains A/WSN/33 (H1N1), A/HK/1/68 (H3N2),
and A/HK/54/98 (H1N1) were propagated in MDCK cells with serum-
freemedium supplementedwith 1g/ml tosylsulfonyl phenylalanyl chlo-
romethyl ketone (TPCK)-treated trypsin (Thermo Scientific), and viral
titers were determined by plaque assay on MDCK cells. Briefly, virus
stocks were serially diluted in phosphate-buffered saline (PBS) (Invitro-
gen, Carlsbad, CA) and adsorbed onto confluent MDCK cells for 1 h at
37°C. Later, the inoculum was removed and cells were washed twice with
PBS and coveredwith an agar overlay (1% agarose, 1g/ml TPCK-treated
trypsin in DMEM). After 3 days of incubation, the cells were stained with
crystal violet and plaques were counted to obtain the virus concentration
as PFU per ml.
Plasmids and antibodies. Plasmid pCMV-myc-AnxA6, correspond-
ing to the DNA sequence of human AnxA6 (GenBank accession no.
NM_001155.3) with a C-terminal myc tag, was purchased from OriGene
Technologies. Plasmid pCMV-AnxA6-GFP was generated by inserting
the AnxA6 open reading frame (ORF) into the pCMV-GFP vector at the
KpnI and NotI restriction sites. For production of an A431 stable cell line
expressing AnxA6, the AnxA6 cDNA containing a myc tag was amplified
from pCMV-myc-AnxA6 using the forward primer AGTCGAACTAGTG
CCGCCATGGCCAAACCAGC and the reverse primer GATGCTGGGC
CCTTACAGATCCTCTTCAGAGATGAGTTTC and subsequently in-
serted into pLenti-6.3/V5-Dest vector (Invitrogen) at the SpeI and ApaI
restriction sites. All constructs were sequenced at the Genome Research
Centre of the University of Hong Kong.
Primary antibodies used in this study were mouse anti-M2 monoclo-
nal antibody (MAb) (clone 14C2; Affinity BioReagent Inc.), mouse
anti-M1 MAb (clone GA2B; Abcam, Cambridge, MA), mouse anti-NP
MAb (cloneAA5H;Abcam),mouse anti-glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH)MAb (clone 6C5; Abcam), mouse anti-mycMAb
(clone 9E10; Sigma, St. Louis, MO), and mouse anti-AnxA6 MAb (clone
73; BD Transduction Laboratories).
Coimmunoprecipitation and Western blotting. HEK 293T cells
grown in 6-cm dishes were transfected with pCMV-myc-AnxA6 plasmid
for 24 h and then infectedwith influenza A/WSN/33 virus at amultiplicity
of infection (MOI) of 0.1. At 24 h postinfection (p.i.), cells were washed
and resuspended in 0.5ml of immunoprecipitation buffer (150mMNaCl,
15 mM EDTA, 1% Triton X-100, 0.25% sodium deoxycholate, and pro-
tease inhibitor cocktail [Roche Diagnostics GmbH]). After centrifuga-
tion, the supernatant was incubated with anti-myc, anti-M2, or normal
mouse immunoglobulin G (IgG) for 2 h. The immune complexes were
recovered by adsorption to protein G-Sepharose beads (Amersham Bio-
sciences,Uppsala, Sweden)overnight at 4°C.Afterfivewashes in immuno-
precipitation buffer, the immunoprecipitates were analyzed by Western
blot analysis.
ForWestern blotting, protein samples were solubilized in LDS sample
buffer (Invitrogen) and 10 mM dithiothreitol (DTT), boiled at 95°C for 8
min, and loaded into a NuPAGE Novex 4 to 12% Bis-Tris minigel for
separation by sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE). Separated proteins were then transferred to a Hybond-P
polyvinylidene difluoride (PVDF) membrane (Amersham Biosciences),
and the membrane was blocked overnight at 4°C in 5% skim milk pre-
pared in PBS-T (PBS containing 0.1% Tween 20). The membrane was
incubated with appropriately diluted primary antibodies for 1 h, washed,
and then incubated with a horseradish peroxidase-conjugated secondary
antibody (1:5,000; Jackson ImmunoResearch). Blots were visualized us-
ing an enhanced chemiluminescence (ECL) system (GE Healthcare). The
protein size was estimated using Novex Sharp prestained protein stan-
dards (Invitrogen).
siRNA treatment and virus infection.Gene-specific small interfering
RNAs (siRNAs) for AnxA6 (M-011210) were provided as an siGENOME
SMARTpool, which is a pool of four siRNAs targeting various sites in a
single gene. AnxA6_17 siRNA (si_AnxA6 [CGGGCAAGUUUGAACGG
UU]) and the nontargeting siRNA 3 (si_Control; D-001210) were pro-
vided as individual siRNA duplexes. All siRNAs and transfection reagents
(DharmaFECT 1 and T-2001) were purchased from Dharmacon (Dhar-
macon Research Inc., Lafayette, CO). Low-passage A549 cells were trans-
fected with siRNA at a concentration of 100 nM for 60 h according to the
manufacturer’s instructions, and the knockdown efficiency was checked
by immunoblot analysis. To study the effect of AnxA6 knockdown on the
replication of influenza virus, three strains (A/WSN/33 [H1N1], A/HK/
1/68 [H3N2], and A/HK/54/98 [H1N1]) were used to infect the siRNA-
treatedA549 cells at anMOI of 0.01. Supernatantswere collected at 24 and
48 h p.i., and the virus titers were determined by plaque assay on MDCK
cells as described above.
Establishment of A431 stable cell lines expressing AnxA6 and virus
infection. The ViraPower lentiviral expression system (Invitrogen) was
used to generate an A431-based stable cell line expressing recombinant
human AnxA6 (A431-AnxA6). The pLenti-AnxA6 construct was gener-
ated as described above. Briefly, subconfluent monolayers of 293T cells
grown in a 10-cm dish were transfected with pLenti-AnxA6 or pLenti-
eGFP transfer vector (5 g), pGag-pol (5 g) packaging plasmid (5 g),
and pVSV-G plasmid (5 g) using a CalPhos transfection kit (Clontech).
At 48 h posttransfection, the cell culturemedium containing pseudotyped
lentiviral particles was harvested and centrifuged to remove cell debris.
The viral supernatant was used directly for infection of A431 cells seeded
into 6-well plates and grown to 70% confluence before infection. Two
days later, cell culturemediumwas replacedwith culturemedium supple-
mented with 5 g/ml blasticidin for selection. The medium was changed
every 2 days, and the surviving clones were propagated and screened for
AnxA6 expression byWestern blotting, flow cytometry, and immunoflu-
orescence assays.
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Immunofluorescence assay. To study the colocalization of AnxA6
and M2 on virus-infected cells, A549 or A431 cells grown on coverslips
were transiently transfected with pCMV-AnxA6-GFP plasmid and then
infected with influenza A/WSN/33 virus at an MOI of 5. A low-
temperature preincubation method was used to allow synchronized in-
fection. At 14 h p.i., cells were fixed with 4% paraformaldehyde (PFA) for
10 min and permeabilized in PBS containing 0.1% Triton X-100 for 10
min. The viral M2 protein was stained with mouse anti-M2 14C2 MAb,
followed by incubation with Alexa Fluor 555-conjugated goat anti-mouse
IgG (Invitrogen). Nuclei were stained with DAPI (4=,6-diamidino-2-
phenylindole), and images were captured with a Zeiss LSM 700 confocal
fluorescence microscope at the Faculty Imaging Core Facility of the Uni-
versity of Hong Kong.
To study the effects of AnxA6 on the early stages of influenza virus
infection, virus infectivity was determined on siRNA-treated (si_AnxA6
or si_Control) A549 cells or A431 cells and the A431-AnxA6 stable cell
line. Briefly, cells grown on glass coverslips in a 24-well plate were infected
with influenza A/WSN/33 virus at anMOI of 5. At 3 h p.i., cells were fixed
and permeabilized in PBS containing 0.1% Triton X-100 for 10 min. In-
direct immunofluorescence was then performed using a mouse anti-NP
MAb as a marker of infection, followed by incubation with Alexa Fluor
555-conjugated goat anti-mouse IgG (Invitrogen). Nuclei were stained
with DAPI to count the total number of cells. Images were acquired using
a Zeiss Axio Observer wide-field inverted fluorescence microscope. The
percentage of infected cells was then calculated using the cell scoring ap-
plication module of Metamorph image analysis software (Molecular De-
vices).
To investigate the effect of AnxA6 depletion on viral protein traffick-
ing, the subcellular localization ofNP andM2was studied. Briefly, siRNA-
treatedA549 cells were infectedwith influenzaA/WSN/33 virus at anMOI
of 5 and fixed at 4, 6, and 8 h p.i. Viral NPwas immunostained as amarker
for export of the vRNP complex, and nuclei were stained with DAPI.
Images of randomly chosenmicroscopic fields of duplicateswere acquired
(200 cells) using a Zeiss Axio Observer wide-field inverted fluorescence
microscope. The percentage of cells with nuclear NP only was determined
using Metamorph image analysis software (Molecular Devices).
Quantitative RT-PCR assay for vRNA and mRNA. siRNA-treated
A549 cells were infected with influenza A/WSN/33 virus at an MOI of 3,
and the total RNA was extracted at 4 h p.i. by using an RNeasy kit
(Qiagen). One microgram of total RNA was reverse transcribed using
SuperScript II reverse transcriptase (Invitrogen). For the detection of viral
genomic RNA (vRNA), a 10Mconcentration of a vRNA-specific primer
complementary to the 3= end of vRNA was used in the reverse transcrip-
tion (RT) reaction mix (26), whereas for mRNA detection, 500 ng of
oligo(dT) primer was used. For quantification of M gene vRNA and
mRNA, a SYBR green-based real-time PCR method (Roche) was used,
and-actinmRNAwas quantified to normalize the total RNA concentra-
tion between different samples, as described previously (29). The primers
for M gene detection were M-F (5=-AAGACCAATCCTGTCACCTCTG
A-3=) and M-R (5=-CAAAGCGTCTACGCTGAGTCC-3=), and those for
-actin detection were B-F (5=-CCCAAGGCCAACCGCGAGAAGAT-
3=) and B-R (5=-GTCCCGGCCAGCCAGGTCCAG-3=). The PCR exper-
iments were performed using a LightCycler system (Roche). A reaction
mix of 20l was composed of 1l of each gene-specific primer at 10M,
10l of SYBR greenmastermix, 5l of 10-fold-diluted cDNA, and 3l of
distilled water. The amplification program was as follows: 95°C for 5 min
followed by 45 cycles of 95°C for 10 s, 60°C for 10 s, and 72°C for 10 s. The
specificity of the assay was confirmed by melting curve analysis at the end
of the amplification program.
Luciferase assay for viral polymerase complex activity. siRNA-
treated 293T cells were cotransfected with pPolI-Luc-RT (36) together
with plasmids encoding PB2, PB1, PA and NP of influenza A/WSN/33
virus. In addition, a green fluorescent protein (GFP) expression plasmid
was also cotransfected, and GFP signals were used for data normalization.
At 48 h posttransfection, cells were lysed and then incubated with Steady-
Glo assay reagent (Promega) for 5 min, and the luminescence was mea-
sured using a luminometer (Victor3; PerkinElmer). Means and standard
deviations were determined for triplicates of two independent experi-
ments.
Flow cytometry. A431 cells and the A431-AnxA6 stable cell line were
infectedwith influenzaA/WSN/33 virus at anMOI of 3. Cells were fixed at
8 and 10 h p.i., and the cell surface-expressed viralM2 protein was stained
using mouse anti-M2 14C2 MAb and Alexa Fluor 488-conjugated goat
anti-mouse IgG (Invitrogen), without permeabilization treatment. After
washing, the cell suspensions were subjected to flow cytometry on an
LSRII flow cytometer (BD Biosciences), and more than 20,000 singlet
living cells were collected. The postacquisition data analysis was per-
formed using FlowJo software (TreeStar).
Electronmicroscopy.Thin-section transmission electronmicroscopy
(TEM) was performed as previously described (1). A431 cells and the
A431-AnxA6 stable cell line were infected with influenza A/WSN/33 virus
at anMOI of 5. At 10 h p.i., cells were washed with PBS and prefixed with
2.5% glutaraldehyde in cacodylate buffer (0.1 M sodium cacodylate-HCl
buffer, pH 7.4) overnight at 4°C. Fixed cells were then scraped off and
pelleted by low-speed centrifugation. After being washed in the same buf-
fer, cells were postfixed with 1% osmium tetroxide for 30 min at room
temperature, dehydrated in increasing concentrations of ethanol, and
embedded in epoxy resin. Ultrathin sections were then stained with 2%
aqueous uranyl acetate and Reynold’s lead citrate. Samples were imaged
on a Philips EM208s electronmicroscope at the ElectronMicroscopyUnit
of the University of Hong Kong.
RESULTS
M2 CT interacts with human AnxA6 in yeast. The IAV M2 ion
channel protein is a highly conserved transmembrane protein and
possesses the longest CT among the three viral envelope proteins.
This 54-residue CT is accessible to the cellular machinery after
fusion with the endosomal membrane and during production,
maturation, and trafficking of viral envelope proteins and virus
assembly and budding (25, 31, 33, 51). We hypothesized that cel-
lular factors interacting with this CT could either help or restrict
processes involving M2. To identify these factors, we performed a
genomic Y2H screen, using IAV M2 CT as bait (Fig. 1A). A
random-primed cDNA library from human placenta was
FIG1 Identification of AnxA6 as a cellular interactant ofM2CT. (A)Diagram
of structural motifs in the M2 protein and sequence of the CT used as bait for
Y2H screening. ED, ectodomain; TM, transmembrane domain. (B) Schematic
representation of full-length AnxA6 and of clones 196 and 270. (a) The eight
repeats of AnxA6 are shownwith gray numbered boxes. Among the 15AnxA6-
positive clones isolated, clone 196 (b) and clone 270 (c) contained the largest
and smallest AnxA6 cDNA fragments, respectively. Numbers indicate amino
acid positions.
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screened (63.89 million interactions were tested), leading to the
identification of 273 positive clones corresponding to 47 cellular
factors. One of the most prominent results of the screen was the
identification of the interaction between M2 CT and human
AnxA6, with a total of 15 positive clones (5%) corresponding to
this protein (GenBank accession number NM_001155.3) (Table
1). This interaction was classified with the highest confidence
score (predicted biological score of A). AnxA6 was not found in
parallel screens performed with other influenza virus baits (data
not shown). Among the 15 AnxA6 cDNA clones, clones 270 and
196 constituted the smallest and largest cDNA fragments, respec-
tively. Sequence alignment of the 15 AnxA6 cDNA clones revealed
a minimal interacting domain located between repeats 2 and 3 of
the first core domain (amino acid residues 44 to 147) (Fig. 1B).
These data indicate that AnxA6 interacts specifically with the IAV
M2 CT in yeast.
M2 binds to AnxA6 in influenza virus-infected human cells.
To confirm the interaction betweenM2CT andAnxA6 during the
IAV life cycle in human cells, we performed coimmunoprecipita-
tion experiments withHEK 293T cells transiently transfected with
a plasmid encoding a myc-tagged AnxA6 protein (myc-AnxA6)
and infected with influenza A/WSN/33 virus. Expression of the
recombinantmyc-AnxA6 and viralM2 proteins was detectedwith
anti-myc and anti-M2 MAbs, respectively (Fig. 2A, upper panel).
Cell lysates were then immunoprecipitated with anti-myc MAb
and subsequently immunoblotted with anti-M2 MAb. As shown
in themiddle panel of Fig. 2A, coimmunoprecipitation ofM2with
AnxA6 was detected, confirming their physical interaction in
virus-infected cells. The specificity of the M2-AnxA6 interaction
was further demonstrated by detection of myc-AnxA6 protein in
reciprocal coimmunoprecipitation assays using anti-M2 MAb
and by the absence of coimmunoprecipitation of myc-AnxA6 in
cell lysate from noninfected cells (Fig. 2A, lower panel). These
results clearly demonstrate that the IAV M2 protein physically
binds to recombinant AnxA6 in virus-infected cells.
To investigate the subcellular localization where the M2-
AnxA6 interaction occurs in infected cells, we performed colocal-
ization studies with A549 cells transiently transfected with a plas-
mid encoding AnxA6 fused to GFP (AnxA6-GFP) (12) and
infected with influenza virus strain WSN at an MOI of 5 for 14 h.
In noninfected but transfected control cells, AnxA6 was evenly
distributed in the cytosol (Fig. 2B, left panels), as reported previ-
ously by others (12, 14). For the infected but nontransfected con-
trol cells, theM2 protein was distributed in intracellular compart-
TABLE 1 Yeast two-hybrid screening for AnxA6-M2 CT interaction
Characteristic Value or description
Bait M2 cytoplasmic tail (aa 44–97)
Library Random-primed human placenta cDNA
No. of interactions tested 63.89 million
Prey AnxA6
No. of positive clones 15
Confidence scorea A
Minimal interacting domain aa 44-147
a Predicted biological score (A to E), a statistical confidence score assigned to each
interaction by Hybrigenics.
FIG2 AnxA6 interacts withM2 in virus-infected human cells. (A) Reciprocal coimmunoprecipitation assay ofmyc-AnxA6 andM2 in 293T cells. 293T cells were
transfected with a plasmid encoding amyc-tagged AnxA6 protein andwere infected 24 h later with A/WSN/33 virus at anMOI of 0.1. Cells were lysed at 24 h p.i.,
and a coimmunoprecipitation assay was performed using either anti-myc (middle panel) or anti-M2 (lower panel) MAb. Immunoprecipitated proteins were
detected by Western blotting using either anti-M2 or anti-myc MAb. The input samples were 10-fold-diluted cell lysates (upper panel). (B) AnxA6 colocalizes
with M2 protein close to the plasma membranes of infected A549 cells. A549 cells were transfected with AnxA6-GFP plasmid and then infected with influenza
A/WSN/33 virus at an MOI of 5 as indicated. Cells were fixed at 14 h p.i., stained with mouse anti-M2 MAb followed by Alexa Fluor 555-conjugated goat
anti-mouse IgG, and analyzed by confocal microscopy. Bars, 10 m.
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ments close to the perinuclear region, suggestive of its localization
at the endoplasmic reticulum and Golgi apparatus and at the
plasma membrane (Fig. 2B, middle panels). For transfected and
infected double-positive cells, there was no change in the M2
staining pattern compared to that of nontransfected infected con-
trol cells. Interestingly, confocal imaging revealed a partial colo-
calization of M2 and AnxA6 in distinct punctum-like areas at or
close to the plasmamembrane of virus-infected cells (Fig. 2B, right
panels, arrows).
Altogether, these results confirm the Y2H result that the IAV
M2 protein physically interacts with AnxA6 in virus-infected hu-
man cells and suggest that the interaction occurs close to or at the
plasma membrane.
AnxA6 negatively modulates influenza virus infection. To
define the role and impact of M2-AnxA6 interaction on the viral
replication cycle, we first studied the effect of AnxA6 gene knock-
down on the replication of IAV in A549 human lung epithelial
cells. Immunoblot analyses confirmed that a pool of AnxA6-
specific siRNA duplexes (data not shown), as well as one individ-
ual siRNA duplex (si_AnxA6), efficiently and reproducibly re-
duced cellular AnxA6 expression levels, but nonspecific control
siRNA (si_Control) did not (Fig. 3A). Using this protocol, we
investigated whether silencing of AnxA6 expression had any im-
pact on the production of infectious influenza virus particles.
Twenty-four hours after infection with influenza virus strain
WSN at anMOI of 0.01, we found that silencing of AnxA6 expres-
sion led to a significant increase (10-fold) of progeny virus titers
in cell culture supernatants compared with those of si_Control-
treated cells (Fig. 3B). In order to test whether this inhibitory role
is also applicable to other IAV strains, two clinical isolates were
tested. Similar enhancements of virus progeny titers were also
observed for influenza A/HK/1/68 (H3N2) (Fig. 3C) and A/HK/
54/1998 (H1N1) (Fig. 3D) viruses at both 24 and 48 h p.i. These
results demonstrate that silencing of AnxA6 expression increases
FIG 3 AnxA6 negatively modulates influenza virus infection. (A) siRNA-mediated gene knockdown efficiency analysis. Cell lysates of siRNA-treated cells were
collected at 60 h posttransfection, and expression levels of the AnxA6 andGAPDHproteins were determined byWestern blotting. (B, C, andD)AnxA6 depletion
in A549 cells increases progeny virus titer. A549 cells treated with the indicated individual siRNAs were infected with influenza A/WSN/33 (H1N1) virus (B),
A/HK/1/68 (H3N2) virus (C), or A/HK/54/98 (H1N1) virus (D) at an MOI of 0.01. Cell culture supernatants were collected at 24 and 48 h p.i., and virus titers
were determined by plaque assay on MDCK cells. Data are shown as means standard deviations (SD) for triplicates from four independent experiments (B)
and duplicates from three independent experiments (C andD). , P 0.01; , P 0.0001 by unpaired Student’s t test. (E) Overexpression of AnxA6 in A431
cells decreases progeny virus titer. A431 cells were used to establish a stable cell line overexpressing AnxA6 that was infected with influenza A/WSN/33 virus at
anMOI of 0.01. Cell culture supernatants were collected at 24 h p.i., and virus titers were determined by plaque assay onMDCK cells. Data are shown asmeans
SD for measurements from quadruplicates in a representative experiment. , P 0.0001 by unpaired Student’s t test. (F) Overexpression of AnxA6 in A431
cells impairs virus propagation. The same experiment as that in panel Ewas conductedwith cell lysates collected at 24 h p.i. Expression levels of viral (M1 andM2)
and cellular (AnxA6 and GAPDH) proteins were determined by Western blotting.
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the production of infectious influenza A virus progeny, suggesting
that AnxA6 negatively modulates IAV infection.
To corroborate these findings, we determined the impact of
AnxA6 overexpression on virus replication. We used the A431
human vulval squamous epithelial cell line, which naturally lacks
endogenous AnxA6 (54), and established an A431 cell line stably
expressing AnxA6 (A431-AnxA6), andwe infected these cells with
influenza virus WSN at an MOI of 0.01. At 24 h p.i., the progeny
virus titer from A431 cells reached 9 103 PFU/ml. In contrast, a
viral titer of 5  102 PFU/ml was measured for the A431-AnxA6
stable cell line (Fig. 3E). Although the virus replicates less effi-
ciently in A431 cells than in A549 cells, a significant decrease of
progeny virus titers was observed with the A431-AnxA6 stable cell
line (18-fold). In addition, the viral M1 and M2 protein levels
were determined by immunoblot analysis at 24 h p.i. As shown in
Fig. 3F, immunoblot analyses confirmed the absence of endoge-
nous AnxA6 and the overexpression of recombinant AnxA6 in
normal A431 and A431-AnxA6 cells, respectively (upper panel),
and showed a clear reduction of viral proteins detected in the
A431-AnxA6 stable cell line (middle panels). These results dem-
onstrate that AnxA6 overexpression decreases the titer of released
infectious influenza virus particles, and they further support the
negative regulatory role of AnxA6 in virus infection.
Collectively, these results demonstrate that modulation of
AnxA6 expression (silencing or overexpression) impacts the pro-
duction of infectious progeny viruses, which confirms that AnxA6
negatively regulates IAV infection and its propagation in human
cell lines.
Modulation of AnxA6 expression does not impair the early
stages of the viral life cycle or viral gene expression. To address
which step(s) of the virus life cycle is regulated by the modulation
of AnxA6 expression, we performed a comprehensive and system-
atic dissection of the viral life cycle. We first wondered whether
silencing or overexpression of AnxA6 might impair the early
stages of the influenza virus life cycle, including viral entry. To
address this point, we determined the virus infectivity in A549
cells pretreated with si_AnxA6 or si_Control and in A431 cells or
theA431-AnxA6 stable cell line after infectionwith influenza virus
WSN at MOIs of 1 and 5, respectively. Cells were fixed at 4 h p.i.
and assayed for infection by immunostaining for NP, and the
percentage of infected cells was determined. Similar fluorescence
signals (Fig. 4A) and comparable percentages of NP-positive cells
(Fig. 4B) were observed for cells treatedwith si_AnxA6 or si_Con-
trol. Similar results were obtained for A431 cells and the A431-
AnxA6 stable cell line, and no significant difference between per-
centages of infected cells was observed (Fig. 4C and D). These
results suggest that modulation of AnxA6 expression does not
impair influenza virus entry or viral gene expression. We further
confirmed this result by investigating the effects of AnxA6 silenc-
ing on HA-mediated viral entry, binding, and internalization, NP
nuclear import after analysis of transduction with HA-
pseudotyped lentiviral particles (HApp) (42), and NP subcellular
localization at early time points of virus infection (30, 60, 120, and
180min p.i.) (13). No significant differencewas observed in trans-
duction,measured asHApp-expressed luciferase activity, or inNP
subcellular localization, showing that virus entry and NP nuclear
import were normal in A549 cells pretreated with si_AnxA6 (see
Fig. S1 in the supplemental material).
To further investigate a potential effect of modulation of
AnxA6 expression on vRNA replication or mRNA transcription,
the copy number of the viralM genewasmeasured by quantitative
RT-PCR at 4 h p.i. on siRNA-treated A549 cells infected with
influenza virusWSN at anMOI of 3. Slight but statistically signif-
icant increases in the copy numbers ofM gene vRNA (Fig. 4E) and
mRNA (Fig. 4F) were detected for infected si_AnxA6-treated cells
(1.3-fold). Nevertheless, we could not observe any change in
protein level for theM1 andM2proteins at the same time point by
immunoblot analysis (Fig. 4G), indicating that modulation of
AnxA6 expression does not affect viral gene expression. In addi-
tion, the potential effect of silencing of AnxA6 expression on viral
polymerase activity was also investigated using an influenza virus
minireplicon system. siRNA-pretreated 293T cells were cotrans-
fected with plasmids encoding the influenza virus WSN polymer-
ase complex proteins (PB1, PB2, PA, and NP), along with a re-
porter plasmid containing noncoding sequences from the
influenza virus M segment as well as the firefly luciferase gene
driven by the human RNA polymerase I promoter (36, 60). Con-
sistently, AnxA6 depletion had no significant effect on the lucifer-
ase reporter enzymatic activity (1.25-fold) (Fig. 4H), suggesting
that modulation of AnxA6 expression does not impair viral poly-
merase activity.
Taken together, these results indicate that the impact of mod-
ulation of AnxA6 expression on production of infectious progeny
viruses does not occur during the early stages of the virus life cycle
or during viral RNA synthesis and gene expression.
Modulation of AnxA6 expression does not impair vRNP ex-
port or M2 protein expression and trafficking. To address
whether silencing of AnxA6 expression could affect vRNP export
to the cytoplasm, NP subcellular localization was analyzed during
the time course of infection of siRNA-treated A549 cells (Fig. 5A).
NP subcellular localization was scored according to whether the
NP staining was predominantly nuclear or cytoplasmic (Fig. 5B)
(43). At 4 h p.i., for both si_AnxA6- and si_Control-treated cells,
NP proteins were found to be mainly nuclear, as expected for an
intermediate time point in the virus life cycle (Fig. 5A, left panels,
and B). For both types of siRNA-treated cells, the percentage of
cells exhibiting nuclear NP decreased with time as NP was pro-
gressively exported to the cytoplasm (Fig. 5A, middle and right
panels, and B). No significant difference in NP subcellular local-
ization was measured between si_AnxA6- and si_Control-treated
A549 cells. This observation indicates that silencing of AnxA6 ex-
pression has no effect on vRNP export to the cytoplasm.
Subcellular localization of viral M2 protein was also analyzed
during the time course of infection of siRNA-treated A549 cells
(Fig. 5C). No difference in M2 subcellular localization was ob-
served between si_AnxA6- and si_Control-treated A549 cells. We
also wondered whether AnxA6 overexpression could affect cell
surface expression ofM2.We quantified cell surface expression of
M2 antigen on nonpermeabilized infected A431 cells and the
A431-AnxA6 stable cell line by using flow cytometry. As shown in
Fig. 5D, no significant change in M2 cell surface expression was
observed at 8 or 10 h p.i. These results indicate that AnxA6 deple-
tion has no effect on M2 cell surface expression.
Taken together, these data indicate that the regulation of pro-
duction of infectious progeny viruses by AnxA6 does not occur
during NP nuclear export or M2 cell surface expression, and they
suggest that a very late stage of the virus life cycle is affected.
AnxA6 modulates influenza A virus replication by disrupt-
ing virus budding processes. To determine whether late stages of
the virus life cycle are regulated by the modulation of AnxA6 ex-
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pression, we reexamined the colocalization of M2 and AnxA6 at
14 h p.i. A431 cells transiently transfectedwith a plasmid encoding
aGFP-fusedAnxA6protein (AnxA6-GFP) (12)were infectedwith
influenza virus strain WSN at an MOI of 5. Compared to A549
cells, A431 cells naturally lack AnxA6 expression, which allowed
us to exclude any interaction between M2 and endogenous
AnxA6. The results obtained were similar to those observed for
A549 cells (Fig. 2B). In noninfected but transfected controls,
AnxA6was evenly distributed in thewhole-cell cytosol (Fig. 6a), as
reported previously by others (12). In infected but nontransfected
control cells, M2 was localized mainly at the cell plasma mem-
brane and also in some punctate areas (data not shown). For
transfected and infected double-positive cells, the M2 staining
pattern was similar to that for infected but nontransfected control
cells (Fig. 6c). However, the distribution of AnxA6 was less dif-
fuse in the cytosol and exhibited many enriched punctate areas
compared with control cells without infection, in which AnxA6
colocalized with M2 (Fig. 6d, arrows and inset). In the z-plane
reconstruction, the confocal imaging revealed that M2 and
AnxA6 colocalized at the plasma membrane (Fig. 6h). This
observation indicates that both proteins most likely interact at
the plasma membrane, where viral assembly and virion bud-
ding occur.
Using thin-section TEM, we examined virus budding and
morphology on the surfaces of A431 cells and the A431-AnxA6
stable cell line after infectionwith influenza virus strainWSNat an
MOI of 5 for 10 h. For A431 cells, consistent with previous obser-
vations of infection with influenza virus WSN (10), a majority of
spherical particles that were 60 to 80 nm in diameter and com-
pletely released from the plasmamembranewas observed (Fig. 7A,
upper panels, asterisks). Some spherical budding virions con-
nected to the cell surface by a neckwere also detected, occasionally
retaining an elongatedmorphology (Fig. 7A, upper panels, arrow-
head). In contrast, in the A431-AnxA6 stable cell line, virions were
more abundant and displayed a higher degree of pleomorphism.
Most virions were viral particles exhibiting an elongated shape
FIG 4 AnxA6 does not affect the early stages of the viral life cycle or viral gene expression. (A and B) Silencing of AnxA6 expression does not affect the early stages
of the viral life cycle. (A) A549 cells treated with the indicated siRNAs were infected with influenza A/WSN/33 virus at an MOI of 5. At 3 h p.i., cells were fixed
and immunostained for NP as a marker of infection. Nuclei were stained using DAPI. Bar, 20m. (B) Percentages of infected (NP-positive) cells (n,100,000)
plotted against the siRNA treatments used. (C and D) AnxA6 overexpression does not affect the early stages of the viral life cycle. The same experiment as that
in panels A and B was performed with the A431-AnxA6 stable cell line and wild-type A431 cells (n,10,000). (E and F) Silencing of AnxA6 expression does not
affect viral RNA replication and transcription. A549 cells treatedwith the indicated siRNAswere infectedwith influenzaA/WSN/33 virus at anMOIof 3, and total
RNAwas then extracted at 4 h p.i. M gene vRNA andmRNA levels were determined by quantitative RT-PCR. Data are shown as means SD for measurements
from triplicates and are representative of 2 independent experiments. (G) Silencing of AnxA6 expression does not affect viral M gene expression. A549 cells
treated with the indicated siRNAs were infected with influenza A/WSN/33 virus at anMOI of 3. Cell lysates were collected at 4 h p.i., and expression levels of viral
(M1 and M2) and cellular (AnxA6 and GAPDH) proteins were determined by Western blotting. (H) Silencing of AnxA6 expression does not affect viral
polymerase complex activity. 293T cells treatedwith the indicated siRNAswere transfectedwith plasmids encoding the polymerase complex components andNP
derived from influenza A/WSN/33 virus, along with a reporter plasmid containing the noncoding sequence from the M segment as well as the luciferase gene
driven by the human polymerase I promoter. Luciferase activity was determined at 48 h posttransfection, and relative activities were compared. Data are shown
as means SD for measurements from triplicates and are representative of 2 independent experiments.
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rather than a spherical one (Fig. 7A, lower panels, arrowheads and
asterisks, respectively). In some rare cases, interconnected virions
were observed, resembling budding-defective influenza virus par-
ticles found in cells depleted of Rab11 (3) or overexpressing vi-
perin (61) or seen when M2 protein is truncated (38). For both
A431 andA431-AnxA6noninfected controls, only smooth plasma
membranes with some filopodial protrusions of 100 nm in diam-
eter and less than 1 m in length were observed (Fig. 7A, left
panels). To confirm these observations, the total number of viri-
ons was determined for both cell types, and virions were catego-
FIG 5 AnxA6 does not affect vRNP export or M2 protein expression and trafficking. (A and B) NP subcellular localization in AnxA6-depleted A549 cells. A549
cells treated with the indicated siRNAs were infected with influenza A/WSN/33 virus at an MOI of 5. Cells were fixed at 4, 6, and 8 h p.i. for immunostaining of
NP as a marker for vRNP complex export, and nuclei were stained using DAPI. Bar, 20 m. Cytoplasmic and nuclear NP localization was quantified using
Metamorph software, and the plotted histogram represents the percentage of infected cells with nuclear NP only. Data are shown as means SD for measure-
ments from at least 200 cells in duplicates of a representative experiment. (C) M2 subcellular localization in AnxA6-depleted A549 cells. A549 cells treated with
the indicated siRNAs were infected with influenza A/WSN/33 virus at an MOI of 5. Cells were fixed at 4, 6, and 8 h p.i. for immunostaining of M2 protein. Bar,
20 m. (D) AnxA6 overexpression does not affect M2 cell surface expression. A431 cells and the A431-AnxA6 stable cell line were infected with influenza
A/WSN/33 virus at an MOI of 3. Cells were fixed at 8 and 10 h p.i., left nonpermeabilized, and labeled with mouse anti-M2 MAb followed by Alexa Fluor
488-conjugated goat anti-mouse IgG for M2 cell surface analysis by flow cytometry. The graph shows the amount of cell surface expression and fluorescence
intensity of the M2 viral antigen.
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rized into three different types according to morphology: spheri-
cal, elongated, and interconnected virions. Interestingly, 4 times
more total virionswere counted in theA431-AnxA6 stable cell line
than in A431 cells (Fig. 7B), and 60.7% of the virions were elon-
gated, while 36.6%were spherical ones (Fig. 7C). For A431 cells, a
reverse distributionwas observed, with 36.1% elongated viral par-
ticles and 63.5% spherical ones. Interconnected virions weremar-
ginal and were observedmostly in the A431-AnxA6 stable cell line
(2.7% compared to 0.4%). Using the same single-cycle replication
conditions, we determined the PFU titers of progeny virus from
normal A431 and A431-AnxA6 cells (Fig. 7D). A significant drop
in virus titer was observed when AnxA6 was overexpressed. Con-
versely, virus titers were increased after siRNA-mediated silencing
of AnxA6 expression in A549 cells at 10, 12, and 14 h p.i. under
single-cycle replication conditions (data not shown). These results
suggest that AnxA6 overexpression impairs or delays viral bud-
ding. Taking these data in conjunction with the larger number of
virions detected on theA431-AnxA6 stable cell line, it appears that
the absence of AnxA6 results inmore efficient budding and release
of infectious viral particles.
Taken together, these results demonstrate that AnxA6 overex-
pression results in defects in virus budding, leading to slower bud-
ding and release of infectious viral particles.
DISCUSSION
Morphogenesis and virus budding of influenza virions comprise a
complex, multistep process that occurs in lipid raft domains on
the apical membrane of infected cells (reviewed in references 41
and 51). This process requires involvement of both host and viral
components. Lipid rafts and actin microfilaments are host com-
ponents that play important roles in virus assembly and budding.
Unlike other enveloped viruses, influenza virus does not utilize
the host endosomal sorting complex required for transport
(ESCRT) machinery to mediate membrane scission and virus re-
lease, suggesting that influenza virus buds independently of the
host ESCRTpathway (reviewed in references 4, 5, and 62). Among
the viral components, it has been suggested that M2 provides this
membrane scissionmechanism, causing budding completion and
virus release. Rossman et al. proposed an influenza virus budding
model (51) in whichM2 interacting with M1 is first recruited to a
cholesterol-rich environment stabilizing the budding site (49).
M2 is then localized to a lower-cholesterol environment at the
neck of the budding virion, where it induces a negativemembrane
curvature, causing membrane scission and release of the progeny
virus (50). Nevertheless, involvement of unknown host factors in
morphogenesis and virus budding cannot be ruled out.
In the present study, we hypothesized that cellular factors in-
teracting with the 54-residue M2 CT could either help or restrict
processes involvingM2. Fewhost factors interactingwithM2have
been identified, and the functional relevance of these interactions
is not fully characterized (21, 55). In order to identify and charac-
terize human cellular regulators of influenza virus infection, we
used a genomic Y2H approach withM2CT as bait. Previous stud-
ies have shown that such an approach was successful for the IAV
PB1 (28), M1 (37), NS1 (35), and NS2 (7) proteins. We identified
a novel interaction between M2 CT and human AnxA6, which
most likely occurs at the plasma membrane, the virus assembly
and budding site. We showed that AnxA6 negatively modulates
influenza virus infection by affecting virus budding, as indicated
by a drop in progeny virus PFU titer in supernatants and an in-
creased number of virions at the surface of A431-AnxA6 cells,
which exhibit an elongated shape rather than a spherical one.
AnxA6 is a member of the annexin family, a conserved multi-
gene family of Ca2-dependent membrane-binding proteins,
which provides a link between Ca2 signaling and membrane
functions (18). It has been demonstrated that AnxA6 interacts
with the 1 and 2 subunits of the AP1-clathrin complex (11) of
the clathrin-mediated endocytosis process, which is exploited by
IAV to enter host cells (32). In the present study, whenAnxA6was
depleted wemeasured no difference in infectivity rate (Fig. 4B) or
transduction with HApp (see Fig. S1 in the supplemental mate-
rial), suggesting that AnxA6 does not affect viral entry. Previous
FIG 6 AnxA6 colocalizes with M2 at the plasma membrane of virus-infected human cells. A431 cells were transfected with a plasmid encoding the AnxA6-GFP
fusion protein and then infected 24 h later with influenza A/WSN/33 virus at anMOI of 5. After fixation at 14 h p.i., cells were stainedwith amouse anti-M2MAb
followed by Alexa Fluor 555-conjugated goat anti-mouse IgG. Single optical sections (upper panels) and representative z-plane reconstructions (lower panels)
are shown. The inset in panel d shows a magnified (3.7) region at the plasma membrane. Arrows indicate colocalization of AnxA6 and M2 at the plasma
membrane. Bar, 10 m.
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studies indicated that AnxA6 has a tumor suppressor activity by
facilitating the Ca2-dependent targeting of p120GAP (GTPase-
activating protein) at the cell plasma membrane, which leads to
inhibition of Ras/Raf-1 activity (59). Interestingly, it has been
shown that inhibition of the Raf signaling pathway results in nu-
clear retention of vRNPs and impairs production of infectious
influenza virus virions (48). In our study, when AnxA6 was de-
pleted we observed no difference in NP subcellular localization
over time, suggesting that NP nuclear export was normal (Fig.
5B). AnxA6 plays important roles in several biological processes
involving host components which are also essential for virus as-
sembly and budding, such as cholesterol, a critical component of
lipid rafts, and cortical actin (reviewed in reference 14). Each step
of virus assembly and budding (i.e., assembly of viral components,
budding initiation, growth, and completion) requires different
interactions with host components, some of which may facilitate
some step(s) of viral budding but may also interfere with other
steps (41).
FIG 7 AnxA6 overexpression impairs influenza virus budding. (A) Analysis of budding virions from AnxA6-overexpressing cells by TEM. A431 cells (upper
panels) and theA431-AnxA6 stable cell line (lower panels)were infectedwith influenzaA/WSN/33 virus at anMOIof 5. At 10 h p.i., cells were fixed andprocessed
for thin sectioning and TEM. Asterisks indicate spherical virions, and arrowheads indicate elongated virions. Noninfected controls are shown on the left. (B)
Semiquantitation of total numbers of virions. Virions observed in infected cells (n 13 cells with100 virions) of each cell type weremanually counted blinded
by five different investigators, and the total numbers of virions were compared. , P  0.0001 by unpaired Student’s t test. (C) Semiquantitation of virions
according to morphology. During counting, virions were categorized into three types according to their morphology and size, as indicated. The numbers of
virions for each type were determined, and their percentages were subjected to unpaired Student’s t test and plotted as means SD (, P 0.0001; , P
0.01; , P 0.05). (D) Progeny virus titration of released virions. The same experiment as that in panel A was performed with cell culture supernatants collected
at 9 h p.i. Virus titers were determined by plaque assay on MDCK cells. Data are shown as means SD for triplicates in a representative experiment. , P
0.0001 by unpaired Student’s t test.
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At a low intracellular Ca2 ([Ca2]i) concentration, AnxA6 is
distributed diffusely throughout the cytosol (14). However, when
[Ca2]i increases, stimulated AnxA6 is targeted to distinct subcel-
lular membrane locations, such as the plasma membrane, endo-
somes, or secretory vesicles. Thus, cytosolic AnxA6 is probably
translocated to distinct subcellular membrane locations upon vi-
rus infection, due to the dysregulation of Ca2 homeostasis ob-
served after IAV infection (24, 58). If AnxA6 is overexpressed and
targeted at the plasma membrane, it has been shown that it inter-
acts with, recruits, and causes the rearrangement of F-actin, re-
sulting in stabilization of the cortical cytoskeleton (40). In the
present study, we have demonstrated that M2 physically interacts
with AnxA6 in infected cells and colocalizes with AnxA6-GFP at
the plasmamembrane of infected cells (Fig. 2A and B, panel i, and
6d and h), where more budding or budded virions with an elon-
gated shape are observed when AnxA6 is overexpressed (Fig. 7A,
B, and C). Rossman et al. showed that M2 localizes to the neck of
budding virions at the virus budding site, using immunogold la-
beling and electron microscopy (50). At the point of membrane
scission, M2 accumulates where its CT is accessible to AnxA6. A
tempting hypothesis would be that AnxA6 serves as a linker to
stabilized cortical F-actin. This linking may affect the M2-
mediated late stage of virus budding and explain the virus budding
completion defect or delay observed by TEM after AnxA6 overex-
pression in A431 cells. Indeed, cortical actin filaments may inter-
fere with themembrane scission step, as actin disruption has been
shown to help in bud release in HeLa (22) and MDCK (53) cells.
AnxA6-mediated changes observed in the cortical actin cytoskel-
etonmay also impact other actin-dependent stages of virus assem-
bly and budding. Recently, it was suggested that an intact actin
network is necessary for clustering of M2 with HA at the virus
assembly site (56), since cortical actin may drive the formation of
protein clusters and/or organize the maintenance of lipid raft do-
mains (19). Moreover, Bruce et al. have shown that release of
influenza virus virions is attenuated when expression of Rab11 is
silenced (3). This small GTP-binding protein is involved in the
trafficking of proteins to the apical membrane in polarized cells
and in actin remodeling. It has further been shown that silencing
of Rab11 expression reduces M2 cell surface expression, indicat-
ing a defect in properM2 transport to the plasmamembrane along
the actin network rather than a direct role for Rab11 inmembrane
scission (50). In the present study, when AnxA6 was overex-
pressed we observed no changes in M2 cell surface expression,
suggesting that AnxA6 instead affects virus budding (Fig. 5D).
Interestingly, AnxA6 can also indirectly regulate cholesterol
homeostasis. Cubells et al. have shown that AnxA6 overexpression
impairs cholesterol export from late endosomes, contributing to
an imbalance in cholesterol homeostasis and to decreased pools of
cholesterol in other compartments, such as the Golgi apparatus
and the plasma membrane (12). In addition, direct visualization
of themembrane lipid structure indicated that AnxA6overexpres-
sion induces a significant decrease of condensed membrane do-
mains (C. Enrich, personal communication). Cholesterol deple-
tion and architectural changes at the plasma membrane induced
by high levels of AnxA6 may have important biological conse-
quences on virus assembly and budding. Indeed, virus assembly
occurs at lipid rafts in the apical plasma membrane, where HA is
supposed to organize the budozone (52). We could therefore hy-
pothesize that AnxA6 overexpression would impair the coales-
cence of HA-containing lipid rafts forming the budozone that is
required for budding initiation. Interestingly, the interferon-
inducible restriction factor viperin has been shown to exert its
effects at the late stages of the influenza virus life cycle, preventing
the release of viral particles by disrupting lipid rafts (61). At the
surface of viperin-expressing cells, 43% of the viral particles were
either budding virions with an abnormally elongated and large
neck or a “daisy chain” structure in which two or more viral par-
ticles appeared to be interconnected. Moreover, in the influenza
virus budding model proposed by Rossman et al., M2 is sequen-
tially located to cholesterol-rich and then lower-cholesterol re-
gions to allow budding initiation/growth and completion steps,
respectively (51). Barman and Nayak have shown that cholesterol
depletion at the plasma membrane of infected cells by use of
methyl--cyclodextrin (MCD) for a short time induces more
rapid virus budding completion and release (2). Indeed, MCD
treatment may favor the association of M2 with lower-cholesterol
regions, triggeringmembrane scission. In the present study, when
AnxA6 was overexpressed we could observe a drop in progeny
virus titer and more virions at the plasma membrane exhibiting a
rather elongated shape than a spherical one (Fig. 7). Intercon-
nected virions were also detected, but they were only marginally
represented. These results do not support the notion that reduc-
tion of cholesterol pools at the plasma membrane upon AnxA6
overexpressionmay facilitate virus budding and release but rather
suggest that it may impair or delay this process. This discrepancy
with MCD-mediated cholesterol depletion might be explained
by the differences between the mechanisms of action of a specific
drug for a short time and a multifunctional host cellular factor
that is constitutively overexpressed and interacts transiently with
its partners. Indeed, AnxA6-mediated reduction of cholesterol
pools at the plasma membrane may favor the association of M2
with lower-cholesterol regions at the point of membrane scission,
where AnxA6 could serve as a linker between M2 and stabilized
cortical F-actin as discussed previously, resulting in a membrane
scission defect.
In the present study, we have demonstrated that AnxA6 inter-
acts with M2 CT and negatively modulates influenza virus infec-
tion by affecting viral budding. We propose that AnxA6 acts as a
host cellular negative regulator of influenza virus infection, by
interacting withM2, which is able to mediate membrane scission,
or by modulating cellular components involved in viral budding,
or both. Using a recombinant mutant WSN influenza virus lack-
ing M2 by mutation of the splicing signal of the M gene (8), no
significant difference in virus titers was observedwhenAnxA6was
silenced or overexpressed, suggesting that regulation of influenza
virus production byAnxA6 is dependent onM2 (data not shown).
The detailed molecular mechanism underlying this AnxA6-
mediated negative modulation of influenza virus budding awaits
further investigation. Work is ongoing to determine the func-
tional correlation between M2-AnxA6 interaction and the defec-
tive viral budding phenotype and the contributions of AnxA6-
mediated plasma membrane changes through cholesterol
homeostasis modulation and cortical actin remodeling.
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